Anthera Approaches Phase III, Prices $40M Public Offering

With launch of its Phase III registration studies for Lupus drug blisibimod imminent, Anthera Pharmaceuticals Inc., of Hayward, Calif., priced an underwritten public offering worth $40 million in gross proceeds to support operations as it goes forward.